Review

The rapidly evolving view of lysosomal storage diseases

Giancarlo Parenti1,2, Diego L Medina1,2 & Andrea Ballabio1,2,3,4,5,*

Abstract

Lysosomal storage diseases are a group of metabolic disorders caused by deficiencies of several components of lysosomal function. Most commonly affected are lysosomal hydrolases, which are involved in the breakdown and recycling of a variety of complex molecules and cellular structures. The understanding of lysosomal biology has progressively improved over time. Lysosomes are no longer viewed as organelles exclusively involved in catabolic pathways, but rather as highly dynamic elements of the autophagic-lysosomal pathway, involved in multiple cellular functions, including signaling, and able to adapt to environmental stimuli. This refined vision of lysosomes has substantially impacted on our understanding of the pathophysiology of lysosomal disorders. It is now clear that substrate accumulation triggers complex pathogenetic cascades that are responsible for disease pathology, such as aberrant vesicle trafficking, impairment of autophagy, dysregulation of signaling pathways, abnormalities of calcium homeostasis, and mitochondrial dysfunction. Novel technologies, in most cases based on high-throughput approaches, have significantly contributed to the characterization of lysosomal biology or lysosomal dysfunction and have the potential to facilitate diagnostic processes, and to enable the identification of new therapeutic targets.

Keywords autophagy; lysosomal biology; lysosomal storage diseases; lysosomes

Subject Categories Autophagy & Cell Death; Genetics, Gene Therapy & Genetic Disease; Organelles

DOI 10.15252/emmm.202012836 | Received 28 May 2020 | Revised 9 November 2020 | Accepted 10 November 2020 | Published online 18 January 2021

EMBO Mol Med (2021) 13: e12836

See the Glossary for abbreviations used in this article.

Introduction

Knowledge on lysosomal storage diseases (LSDs) has been evolving for more than a century (Fig 1). The first phenotypes and clinical entities were described in the 19th century (see Mehta et al, 2006 for review), long before the identification of lysosomes and the definition of their biochemistry and pathophysiology. At that time, the identification of these disorders was exclusively based on the characterization of clinical phenotypes and pathology.

The biochemical and cellular bases of LSDs were elucidated much later, when Christian de Duve’s work, corroborated by Alex B. Novikoff’s electron microscopy observations, led to the identification of lysosomes as cellular catabolic stations (de Duve et al, 1955; Novikoff et al, 1956), and when the biochemical defects underlying some of the previously described clinical entities were discovered. Pompe disease was the first disorder to be identified as an LSD in 1963, when Henri G. Hers demonstrated that this disease is due to the lack of an acidic α-glucosidase, similar to rat liver lysosomal maltase (Hers, 1963), and that this deficiency is responsible for glycogen storage in tissues. He also suggested that other diseases, such as the mucopolysaccharide storage diseases, might be due to enzyme deficiencies. Between 1960 and the mid-70s, the biochemistry of LSDs was further characterized with the identification of the primary storage materials for other LSDs and the recognition of the respective enzyme deficiencies (Van Hoof, 1974).

For decades, the biology and function of lysosomes remained associated with their catabolic function, and LSD pathophysiology was seen as a direct consequence of defective degradation and disposal of complex substrates (Vellodi, 2005; Heard et al, 2010).

Between the late 1970s and 1990s, research in this field progressed with studies that considerably expanded the knowledge on lysosome biology and on the pathophysiology of LSDs. These studies led to the characterization of the mechanism underlying the sorting of lysosomal enzymes (Sly & Fisher, 1982) and to the identification of the molecular bases of clinical variability of LSDs (Beck, 2001; Kroos et al, 2012).

Following the recognition of the mannose-6-phosphate pathway’s role in lysosomal enzyme trafficking and the availability of new technologies for the purification and manufacturing of lysosomal enzymes, the early 1990s inaugurated the first attempts to treat these disorders by replacing the defective enzyme activity (Barton et al, 1990; Barton et al, 1991).
At the same time, the introduction of novel technologies had a critical role in the study of LSDs. Techniques for targeted gene disruption and generation of knock-out animal models for human LSDs provided tools to better characterize the pathophysiology of these disorders and to develop innovative therapeutic strategies (Pastores et al., 2013). Mass spectrometry technology allowed for lysosomal proteome analyses (e.g., mannose-6-phosphate glycoproteome) (Sleat et al., 2005) that led to the identification of lysosomal proteins and novel molecular bases of some LSDs.

In the past decade, a number of studies have expanded our knowledge of lysosomal biology and provided new and important insights on LSD pathophysiology. These studies identified the lysosomes as highly dynamic organelles involved in multiple cellular functions, including signaling, and able to adapt to environmental stimuli. (Settembre et al., 2013; Perera & Zoncu, 2016; Ballabio & Bonifacino, 2020).

Significant advancements have also facilitated greater understanding on the molecular and metabolic mechanisms underlying LSDs and the development of new therapeutic strategies for these diseases (Parenti et al., 2015; Platt et al., 2018; Ren & Wang, 2020). This review will focus on new tools and technologies to study LSDs, on emerging aspects of lysosomal biology, and on recent discoveries on the cellular and organismal consequences of lysosomal dysfunction.

### The biology of lysosomes, old concepts and new views

Lysosomes are membrane-limited, ubiquitous, intracellular organelles involved in multiple cellular processes (Saftig & Klumperman, 2009; Ballabio & Bonifacino, 2020).

More than two hundred lysosomal-resident proteins contribute to the biology and function of these organelles. Approximately 60 of them are acidic hydrolases (Lubke et al., 2009; Schroder et al., 2010). Most of them act as exoglycosidases or sulfatases and are localized to the lysosomal lumen. The others are localized at the lysosomal membrane and have multiple functions such as formation of a glycosylphosphatidylinositol anchor, transport across the membrane, acidification, membrane stability, and mediating interaction between lysosomes and other cellular structures (Saftig & Klumperman, 2009; Ballabio & Bonifacino, 2020). In addition to lysosomal-resident proteins, other proteins interact with the lysosome and participate to lysosomal function by being dynamically recruited to the lysosomal surface under certain conditions, for example, the transcription factor EB (TFEB), the mechanistic target of rapamycin complex 1 (mTORC1) (Perera & Zoncu, 2016; Ballabio & Bonifacino, 2020; Yim & Mizushima, 2020), the mTORC1 regulator tuberous sclerosis complex (TSC) (Dibble & Cantley, 2015), folliculin (FLCN) and FLCN-interacting protein (FNIP) (Lawrence et al., 2019), the energy-sensing complex AMP-activated kinase (AMPK) (Zhang et al., 2014), and the signal transducer and activator of transcription-3 (STAT3) (Liu et al., 2018).

The first function of normal lysosomes to be recognized is turnover of cellular constituents. Lysosomes are involved in the degradation of a broad variety of structurally diverse compounds, such as proteins, glycosaminoglycans, sphingolipids, oligosaccharides, glycogen, nucleic acids, and complex lipids. Cellular and extracellular materials and substrates destined for degradation reach lysosomes through different routes (endocytosis, phagocytosis, autophagy), or by direct transport. In this respect, lysosomes are part of a more complex pathway, referred to as the autophagy–lysosomal pathway (ALP). Autophagy plays a crucial role in cell homeostasis by controlling intracellular clearance and recycling of a variety of molecules and cellular components and also by sustaining cellular energy metabolism. Autophagy is a multistep pathway that involves autophagosome formation, cargo recruitment, and autophagosome–lysosome fusion. Importantly, autophagic function is entirely dependent on the ability of the lysosome to degrade and recycle autophagy substrates (Yim & Mizushima, 2020).

Much attention has been paid in recent years to the nutrient-sensing function of lysosomes. Lysosomes are able to monitor the

---

**Glossary**

**Autophagy**
A multistep and regulated pathway that removes unnecessary or dysfunctional cellular components and allows for delivery of cargo materials to lysosomes, where they are degraded and recycled.

**High-content imaging**
Cell-based technologies based on automated microscopy and complex image algorithms to extract multidimensional information on cell morphology, fluorescence intensity, or distribution of fluorescent markers within cells.

**Genome editing and CRISPR-Cas9**
An RNA-guided targeted genome editing tool: This methodology which allows to introduce different specific genetic changes such as gene knock-out, knock-in, insertions, and deletions in cell lines and in vivo.

**Lysosomes**
Membrane-limited, ubiquitous, intracellular organelles involved in multiple cellular processes, such as catabolism and recycling of complex molecules and cellular components, signaling, and adaptation to environmental stimuli.

**Metabolome analyses**
High-throughput methodologies for the detection of multiple metabolites, mainly based on mass spectrometry or nuclear magnetic resonance-based approaches.

**Next-generation sequencing**
A diagnostic tool based on technological platforms that allow for sequencing of millions of small fragments of DNA in parallel. Next-generation sequencing can be used either for “targeted” sequencing of selected gene panels or for “untargeted” approaches based on whole-exome or genome analysis.

**MicroRNAs**
Small non-coding RNAs that that regulate gene expression by targeting messenger RNAs.
Recent studies have provided compelling evidence that lysosomal biogenesis and autophagy are controlled by the master transcriptional regulator transcription factor EB (TFEB) (Sardiello et al., 2009; Settembre et al., 2011). In addition to TFEB, another member of the MiT-TFE family of transcription factors, TFE3, has a partially redundant function and is regulated in a similar manner (Martina et al., 2013; Raben & Puertollano, 2016). Unlike other substrates of mTORC1, TFEB is known to interact with RagGTPases (Martina & Puertollano, 2013). Due to this interaction, TFEB phosphorylation occurs through an mTORC1 substrate-specific mechanism that is strictly dependent on the amino acid-induced activation of RagC and RagD GTPases but is insensitive to Rheb activity induced by growth factors. This allows mTORC1 activity to be differentially regulated by different stimuli (Napolitano et al., 2020). This substrate-specific regulation of TFEB by the mTORC1 pathway has a crucial role in Birt–Hogg–Dubé syndrome, a disorder characterized by benign skin tumors, lung, and kidney cysts and renal cell carcinoma (Kaufman et al., 2014; Calcagni, et al., 2016) and caused by mutations in the lysosomal RagC/D activator folliculin (FLCN) (Napolitano et al., 2020).

Lysosomes are emerging as calcium (Ca\(^{2+}\)) storage organelles. The concentration of free Ca\(^{2+}\) within the lysosome is around 500 µM, and therefore comparable to endoplasmic reticulum (ER) Ca\(^{2+}\) levels (Christensen et al., 2002). Ca\(^{2+}\) channels, such as transient receptor potential mucolipin-1 (TRPML-1, Mucolipin 1, MCOLN1) and the two-pore channel (TPC), reside on the lysosomal

**Figure 1. The evolution of the knowledge on LSDs.**

After the identification of the first clinical phenotypes during of the 19th century, the knowledge on LSDs evolved following the recognition of lysosomes in 1955/56 and the demonstration of the biochemical defects underlying LSDs, starting from 1963. Between the 1970s and 1990s, research in this field was focused on the mannose-6-phosphate receptor pathway and on the mechanisms underlying the sorting of lysosomal enzymes, on the identification of the molecular bases of LSDs, and on the development of tools and strategies to investigate lysosomal biology. The first attempts to treat these disorders by enzyme replacement therapy started in the 1990s. Current research is now focusing on the role of lysosomes as signaling platforms controlling cellular metabolism and on the development of new therapeutic approaches.
membrane and have been shown to mediate local Ca\(^{2+}\) signals from intracellular compartments (e.g., mitochondria) (Xu et al., 2015; Xu & Ren, 2015). Lysosomal Ca\(^{2+}\) signaling participates in multiple cellular processes such as lysosomal acidification, the fusion of lysosomes with other cellular organelles, membrane trafficking and repair, autophagy, and formation of contact sites between the lysosome and the endoplasmic reticulum (Kilpatrick et al., 2013; Lloyd-Evans & Waller-Evans, 2019). Furthermore, lysosomal Ca\(^{2+}\) signaling is involved in the regulation of lysosomal biogenesis and autophagy through the activation of TFEB. Upon starvation, lysosomal Ca\(^{2+}\) release through TRPML1 activates the Ca\(^{2+}\)-dependent serine/threonine phosphatase calcineurin (CaN), which binds and dephosphorylates TFEB, thus promoting its nuclear translocation (Medina et al., 2015). TRPML1 also induces autophagic vesicle biogenesis through the generation of phosphatidylinositol 3-phosphate (PI3P) and the recruitment of essential PI3P-binding proteins to the nascent phagophore in a TFEB-independent manner (Scotto-Rosato et al., 2019).

The nosography of LSDs

LSDs are multisystem disorders that are associated with a broad range of clinical manifestations affecting multiple organs and systems and causing visceral, ocular, hematologic, skeletal, and neurological signs. These manifestations are often highly debilitating, causing progressive physical and neurological disabilities.

In general, LSD presentations show broad variability (Beck, 2001), ranging from early-onset (in some cases neonatal), severe clinical forms that often result in premature death of patients, to late-onset, attenuated phenotypes that have a lesser impact on patient health and lifespan. Albeit individually rare, their cumulative incidence is estimated in approximately 1 in 5,000–7,500 births, with higher rates in specific populations. It is noteworthy that newborn screening programs for LSDs, now active in some countries, may in the future significantly change these estimates and will likely provide a more precise figure of LSD incidence (Spada et al., 2006; Hopkins et al., 2018; Wasserstein et al., 2019).

The nosography of LSDs has evolved over time, reflecting the advancements in the knowledge of lysosomal function and the cellular consequences of its dysfunction. The traditional classification based on the classes of stored substrates (glycosaminoglycans in the mucopolysaccharidoses, glycosphingolipids in the glycosphingolipidoses, glycoproteins in the oligosaccharidosis, etc) largely reflects the vision of lysosomes as catabolic organelles and is centered on the disease biochemistry. Accurate and exhaustive information on the disease basis and stability of multienzymatic complexes (galactosialidosis, due to the lack of an enzyme converting a cysteine into a formylglycine residue in the catalytic site of sulfatases) (Cosma et al., 2002; Dierks et al., 2002), or to defective sorting of lysosomal enzymes to lysosomes (mucolipidoses—ML—II and III, with deficient generation of mannose-6-phosphate) (Hickman & Neufeld, 1972). Others are due to mutations of non-enzymatic activator proteins (saposin activator protein, SAP, deficiencies) (Tamargo et al., 2012), of solute carriers (cystinosis, infantile sialic acid storage disease) (Gahl et al., 1982; Verheijen et al., 1999) and other lysosomal membrane proteins (Danon disease, due to LAMP2 defective function) (Nishino et al., 2000; Tanaka et al., 2000), or are the consequence of defects in assembly and stability of multienzymatic complexes (galactosialidosis, due to cathepsin A deficiency) (d’Azzo et al., 1982).

New technologies and cellular modeling to study lysosomal function in health and disease

Novel technologies have had significant impacts on the characterization of lysosome biology, the development of diagnostic tools for patients with a suspicion of LSD, and the identification and validation of new therapeutic targets (Fig 2) (Table 1). In several cases, these approaches are based on high-throughput techniques combined with bioinformatic analysis of a large body of information (metabolomic, genomic, proteomic approaches). Novel approaches also include automated robotic-based, miniaturized or cell-based procedures (high-content imaging) as well as innovative techniques that allow for manipulation of genetic information and generation of in vitro and in vivo models of disease.

Genomic techniques and next-generation sequencing (NGS)

A major advancement, particularly in the diagnostic approach to LSDs, was introduced by NGS, a powerful diagnostic tool based on technological platforms that allow sequencing of millions of small fragments of DNA in parallel. This technology has been used both through a targeted strategy with gene panels and by untargeted approaches based on whole-exome sequencing.

Given the difficulties in the diagnostic work-up, and due to overlapping clinical phenotypes in LSDs, patients with a clinical suspicion of these disorders are excellent candidates for the application of an NGS-based diagnosis. Before the introduction of NGS, the traditional approach for the diagnosis of LSDs was based on a step-by-step, progressive process starting with physical examination, proceeding to metabolite identification in biological fluids, and leading to the exact diagnosis through the demonstration of an enzymatic deficiency (or the deficiency of a lysosomal function) and the identification of mutations in a specific gene (Winchester, 2014).

NGS-based approaches are substantially changing this stepwise process. The molecular analysis and search for mutations in LSD-related genes can be performed immediately after the clinical suspicion of LSD, whereas the functional analysis of the deficient enzyme (or a non-enzymatic protein) offers a complementary approach to definitively confirm disease diagnoses. Such a diagnostic process may prove to be cost-effective and by-pass the need for multiple biochemical analyses or repeated hospital admissions. Some examples of this strategy are already available in the literature, with the development of a gene panel specific for 891 genes involved in the ALP function (Di Fruscio et al., 2015), or the identification of Pompe disease patients in cohorts of unidentified limb-girdle muscular dystrophies (Savarese et al., 2018).
NGS-based analysis also has the potential to identify new genes involved in lysosomal disorders, thus expanding the list of LSDs. Indeed, two novel disorders associated with lysosomal abnormalities and impaired vesicle trafficking were recently recognized through whole-exome sequencing. Mucopolysaccharidosis plus (MPS-plus), characterized by typical manifestations of mucopolysaccharidoses such as coarse facial features, skeletal abnormalities, hepatosplenomegaly, respiratory problems, and by remarkable levels of glycosaminoglycans excretion in urines (Kondo et al., 2017), was associated with mutations in the VPS33A gene (Pavlova et al., 2019). Loss-of-function VPS16 gene mutations were found in patients with an early-onset dystonia and with ultrastructural lysosomal abnormalities (Steel et al., 2020). Both VPS33A and VPS16 genes encode for subunits of the homotypic fusion and vacuole protein sorting (HOPS) complex that is essential for lysosome fusion with endosomes and autophagosomes (Wartosch et al., 2015).

Genomic approaches may also contribute to the understanding of the complexity and clinical variability of LSDs. The application of these approaches to the study of LSDs is a vast and rapidly expanding field that has been comprehensively reviewed in recent years (Hassan et al., 2017; Davidson et al., 2018).

Genome-wide association studies have been performed to identify modifiers in some LSDs, for example, Gaucher disease and Pompe disease. In Gaucher disease, single nucleotide polymorphisms (SNPs) within the CLN8 gene locus were in linkage disequilibrium and associated with disease severity, possibly regulating sphingolipid sensing and/or in glycosphingolipid trafficking (Zhang et al., 2012). In Pompe disease, a c.510C > T variant was identified as a genetic modifier in late-onset patients. This variant negatively influences pre-mRNA splicing in patients carrying the c.-32-13T > G mutation, with significant correlations with residual alpha-glucosidase activity and may be predictive of clinical course and outcome in late-onset patients (Bergsma et al., 2019).

Transcriptomic analysis has been performed in several types of LSDs, such as Niemann-Pick disease type C (Martin et al., 2019), mucopolysaccharidoses (Salvalaio et al., 2017; Peck et al., 2019), progranulin deficiency (Evers et al., 2017), Pompe disease (Turner et al., 2016), and Gaucher disease (Dasgupta et al., 2013), mucolipidosis type IV (Cougnoux et al., 2019). Although the animal models and the tissues differed in these analyses, it was possible to recognize a few common patterns in some diseases. In mucolipidosis type IV mouse microglia, the mixed neuroprotective/neurotoxic expression pattern showed similarities with that observed in Niemann-Pick disease type C1 (Cougnoux et al., 2019). Of note, the changes observed in mucolipidosis type IV microglia overlapped with alterations found in common neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. The analysis...
of mid-cervical cord in the mouse model of Pompe disease showed up-regulation of pathways associated with cell death, proinflammatory signaling, and dysregulation of signal transduction pathways suggestive of impaired synaptic function and plasticity (Turner et al., 2016). Transcriptional analysis in Gaucher disease mice revealed dysregulation of genes involved in cell growth and proliferation, cell cycle, heme metabolism, and mitochondrial dysfunction in liver, lung, and spleen (Dasgupta et al., 2016). Albeit interesting, these data are largely affected by heterogeneity of the samples, indicating the need for integrated and systematic approaches in homogenous animal and cellular models.

In addition to disease mechanisms, NGS-based analysis also has the potential to identify novel disease biomarkers. This approach has been used in recent studies that identified microRNAs as markers of Pompe disease, with correlations between disease phenotype and severity, and possibly with the response to enzyme replacement therapy (Cammarata et al., 2018; Tarallo et al., 2019; Carrasco-Rozas et al., 2019). In Pompe disease, this analysis showed altered expression of microRNAs implicated in signaling pathways related to the pathophysiology of the disease like the mTOR and AMPK pathways, ubiquitin-mediated proteolysis, cardiac hypertrophy, muscle atrophy, and regeneration, regulation of stem cells pluripotency and myogenesis. One of the differentially expressed microRNAs, miR-133a, was identified as a potential marker of disease severity and response to therapy (Tarallo et al., 2019).

In Fabry disease, some of the dysregulated microRNAs are also related to the disease pathophysiology, such as miR-199a-5p and miR-126-3p that are known to be involved in endothelial dysfunction, and miR-423-5p and miR-451a that are involved in myocardial remodeling (Cammarata et al., 2018).

| Table 1. Examples of application of novel technologies for LSDs. |
| Technology | Applications | Examples of successful applications |
| Genomic sequencing | • Diagnosis of LSD patients and identification of mutations of known genes  
• Identification of mutations in genes not associated with LSD | Identification of new LSDs caused by mutation of the VPS33A (Pavlova et al., 2019) and VPS16 (Steel et al., 2020) genes |
| Transcriptomic analysis | • Information on pathways involved in disease pathophysiology  
• Response to environmental conditions/pharmacological manipulations | Similarities between the microglia expression profiles of LSDs (mucolipidosis type IV mouse and Niemann-Pick disease type C1) with common neurodegenerative disorders (Cougouex et al., 2019) |
| Genome-wide association studies | • Identification of modifying factors  
• Information on disease pathophysiology | Identification of a C5L10C > T variant that may be predictive of clinical course and outcome in late-onset Pompe disease patients (Bergsma et al., 2019) |
| microRNA sequencing | • Identification of disease biomarkers that correlate with disease severity and assist in monitoring disease progression and efficacy of therapies  
• Identification of pathways involved in disease pathophysiology | Identification of differentially expressed microRNAs potentially predictive of disease severity in Pompe disease (Tarallo et al., 2019) |
| Biochemical and metabolomic analyses | • Support and validation of diagnosis  
• Identification of disease biomarkers that correlate with disease severity, monitoring disease progression, monitoring efficacy of therapies  
• Newborn screening  
• Identification of pathways involved in disease pathophysiology | Identification of disease biomarkers for several LSDs (Boutin & Auray-Blais, 2015; Reunert et al., 2015; Polo et al., 2019)  
Development of methods for simultaneous detection of multiple enzyme activities in dried blood spots suitable for newborn screening programs for several LSDs (Anderson, 2018; Donati et al., 2018; Kumar et al., 2019; Lukacs et al., 2019; Scott et al., 2020) |
| Cell-based assays and high-content imaging technologies | • Identification of pathways involved in disease pathophysiology  
• Screening for correctors and therapeutic agents | Development of multiplex staining assays that allow screening of FDA-approved compounds and identification of correctors for cellular phenotypes of LSDs (Pipalia et al., 2006; Pugach et al., 2018) |
| Targeted gene knock-out and genome editing—iPSc | • Identification of pathways involved in disease pathophysiology  
• Screening and validation of therapeutic agents  
• Gene editing of mutant genes to correct disease-causing mutations | CRISPR-Cas9-mediated generation of knock-out models of LSDs, such as sphingolipidoses and Niemann-Pick disease type C (Santos & Amaral, 2019) |
| Organellar omics | • Information on lysosome biology  
• Identification of pathways involved in disease pathophysiology  
• Identification of disease biomarkers for correlations with disease severity, monitoring disease progression, monitoring efficacy of therapies | Identification of lysosomal proteome and interactome (Sleaf et al., 2005; Abu-Reimalieh et al., 2017; Thelen et al., 2017; Rabanal-Ruiz & Korolchuk, 2018) |
Biochemical, metabolomic analyses, and newborn screening for LSDs

New technologies for high-throughput analysis of multiple metabolites have also significantly contributed to the diagnostics and monitoring of LSDs. The availability of measurable and objective disease markers remains a major challenge for many LSDs.

Clinical measures are often non-specific (such as the 6-min walk test, respiratory function tests, quality of life assessments) or can be influenced by inter- and intra-investigator variance. Biochemical markers may complement these clinical measures and provide accessory, quantitative tools to follow disease course and patient response to therapies. The search for biochemical markers has benefited from a number of modern methodologies such as mass spectrometry or nuclear magnetic resonance-based approaches. Mass spectrometry has become the most widely used platform for inborn metabolic diseases because of its ability to analyze a wide range of molecules in different body fluids, with optimal dynamic range and great sensitivity (Costanzo et al., 2017). Metabolome analyses have been performed in some LSDs, such as some mucopolysaccharidoses (Fu et al., 2017; Tehani et al., 2019), Fabry disease (Boutin & Auray-Blais, 2015), Pompe disease (Sato et al., 2017), Niemann-Pick disease type C (Fan et al., 2013; Maekawa et al., 2015; Probert et al., 2017), neuronal ceroid lipofuscinoses (Sindelar et al., 2018), or in some sphingolipidoses (Polo et al., 2019).

This approach has allowed the identification of markers that may serve to facilitate early-stage diagnosis and monitoring of response to therapy, for example, galabiosyl ceramide analogs in Fabry disease (Boutin & Auray-Blais, 2015), oxysterols in Niemann-Pick disease type C2 (Reunert et al., 2015), and various sphingolipids in some sphingolipidoses (Reunert et al., 2015). However, some issues need to be addressed in these studies, such as those related to the heterogeneity of samples used for the analyses and the number of patients required to be recruited in order to satisfy statistical significance (Percival et al., 2020).

Tandem mass spectrometry and digital microfluidic fluorimetry (DMF-F) have found important applications in the context of neonatal screening programs (Burlina et al., 2018; Gelb et al., 2019).

The first trials of newborn screening for LSDs started about two decades ago with an immunoassay for the lysosomal marker lysosomal-associated membrane protein-1 (LAMP-1) in dried blood spots (Ranieri et al., 1999). Other approaches followed, such as a multiplex immune-quantification assay of lysosomal enzymes (Meikle et al., 2006), enzyme assays by DMF-F, and tandem mass spectrometry (Gelb et al., 2019). Methods to test lysosomal enzyme activities in dried blood spots suitable for newborn screening programs have been developed for Fabry disease, Gaucher disease, Krabbe disease, Niemann-Pick A/B, Pompe disease, and mucopolysaccharidoses, and for less prevalient disorders such as alpha-mannosidosis, alpha-fucosidosis, lysosomal acid lipase deficiency, and ceroid lipofuscinosis 1 and ceroid lipofuscinosis 2 (Anderson, 2018; Donati et al., 2018; Kumar et al., 2019; Lukacs et al., 2019; Scott et al., 2020). In most instances, these methods allow for simultaneous detection of multiple LSDs (Kumar et al., 2019; Lukacs et al., 2019; Hong et al., 2020).

These screening programs, already active in several countries (Schielen et al., 2017), have had a significant impact on the care of LSDs, allowing early diagnosis and timely access to therapies (Chien et al., 2009) and have changed the figure of LSD prevalence in different countries and populations (Spada et al., 2006).

Cell-based assays and high-content imaging technologies

Together with robotics, the development of cell-based assays in combination with high-content imaging technologies for screening has represented a major and fascinating advance for diseases that are associated with an evident cellular phenotype. Cell-based high-content imaging usually exploits automated microscopy and complex image algorithms to extract multidimensional information from hundreds of samples, such as cell morphology, fluorescence intensity, or distribution of fluorescent markers within cells (Bellomo et al., 2017). Results usually have very high statistical power, due to the high number of cells that can be analyzed allowing averaging of large amount of data. The major advantage, however, is represented by the possibility of multiplexing different assays simultaneously in integrated cell populations, cell subpopulations, individual cells, and subcellular structures within a given population (Zanella et al., 2010; Peravali et al., 2011). For these reasons, high-content imaging is currently used to study disease mechanisms by loss-of-function and gain-of-function studies, as well as in preclinical drug discovery including target identification, lead optimization, assay validation, or primary and secondary screenings (Bellomo et al., 2017).

Several studies substantiate the potential of cell-based screening approaches to identify candidate molecules for the treatment of LSDs, some of them exploiting high-content imaging assays. For example, lysotracker and filipin fluorescence staining assays, or multiplex staining with dual markers filipin and anti-LAMP1 have been exploited to screen FDA-approved compounds and identify correctors of Niemann-Pick disease type C1 (Pipalia et al., 2006; Pugach et al., 2018). One such drug is the antimicrobial alexidine dihydrochloride that appeared to promote increases in NPC1 transcript and mature protein and to be a potent cholesterol-reducing drug. A cell-based assay was also developed to detect arylsulfatase A residual activity in cells from patients with metachromatic leukodystrophy (Geng et al., 2011). Furthermore, a cell-based assay was used to identify three compounds that enhance galactocerebroside activity (Jang et al., 2016). Another phenotypic-based approach was used to identify modulators of autophagy in a murine neuronal cell model of CLN3 disease and led to the identification of compounds that normalized lysosomal positioning and promote clearance of storage material (Petcherski et al., 2019).

In summary, together these data, albeit preliminarily, suggest that cell-based screening approaches may lead to the development of novel therapeutics for lysosomal storage diseases.

Targeted gene knock-out and genome editing techniques

Recently, the development of CRISPR/Cas9 approaches for genome editing and the technology for the generation of induced pluripotent stem cells (iPSCs) from skin or blood samples have opened a new era for the development of disease-relevant cellular models of genetic diseases. These tools have found particular application for the generation of drug-based screening systems and for the study of disease pathophysiology. iPSCs derived from patients are pluripotent and capable of differentiating into virtually any cell type, including disease-relevant neuronal subtypes (Khrana et al., 2015) that display major common features of LSD pathology such as autophagic, lysosomal maturation, and mitochondrial defects (Lojewski et al., 2014). However, a major inconvenience of patient-derived iPSCs is their genetic diversity. The use of (CRISPR)-Cas9...
gene editing to introduce specific genetic changes into a parental pluripotent line allows the production of isogenic lines representing selected mutations of LSD genes that can more readily be compared (Chaterji et al., 2017). CRISPR-Cas9 is currently being exploited to generate knock-out models for the study of LSDs. An exhaustive review about modeling of both cellular and in vivo modeling of rare sphingolipidoses and Niemann-Pick disease type C, using this technology, has been published recently (Santos & Amaral, 2019).

Both CRISPR-Cas9- and iPSC-based approaches offer unprecedented opportunities for the generation of cellular models of LSDs. These can be used for the identification of new pathways involved in the physiology and pathogenesis of LSDs and for drug screenings to identify of new drugs for the therapy of these diseases. Additionally, CRISPR/Cas9 can be by itself an alternative therapeutic option for treating LSDs by correcting disease-causing mutations, both in vitro and in vivo (Schwanck et al., 2013; Wu et al., 2013; Xie et al., 2014).

Targeted gene knock-out and knock-in technologies have found important applications in the generation of in vivo models of LSDs. Compared to in vitro systems, animal models have major advantages as they provide opportunities to study pharmacokinetics, bioavailability, toxicity of therapeutic agents, and to evaluate critical endpoints such as metabolic responses in organs and tissues, and functional measures (Moro & Hanna-Rose, 2020). Animal models have been developed for nearly all LSDs (Vaquer et al., 2013), the majority in small, prolific species such as mice and rats (Vaquer et al., 2013; Gurdà & Vite, 2019). Knock-in animal models have peculiar advantages as they allow characterization of the phenotypic, pathologic, and functional consequences of specific mutations found in patients (Praggastis et al., 2015) or for testing the response of such mutations to experimental treatments (Khanna et al., 2010).

**Organellar omics**

The characterization of the lysosomal proteome has been exploited as an important tool for the understanding of lysosomal dysfunction in human disease and of LSD pathophysiology. Proteomic analysis of lysosomes is mainly based on tandem mass spectrometry and has already proven to be a suitable strategy for the analysis of proteins interactions (Sleat et al., 2005), for the identification of biomarkers (Cologna et al., 2012; Matafora et al., 2015), for the identification of the molecular bases of LSDs, such as CLN2 (Sleat et al., 1997) and NPC2 (Naureckiene et al., 2000), and for the identification of novel potential lysosomal membrane transporters (Chapel et al., 2013).

Proteome analyses in LSD animal models and in selected samples from patients have been performed for Krabbe disease (Pellegrini et al., 2019), mucolipidosis III (Di Lorenzo et al., 2018) ceroid lipofuscinoses (Sleat et al., 2019), Niemann-Pick type C1 (Pergande et al., 2019), in some mucopolysaccharidoses (Yuan et al., 2019), and others. In recent years, in light of the emerging role of lysosomes as signaling platforms controlling cellular metabolism, this approach has attracted renewed and growing interest. Depending on the studies, approximately 200 proteins have been identified, including *bona fide* lysosomal and lysosomal-associated proteins. Interestingly, most of the lysosomal-associated proteins correspond to members of the mTORC1 complex (Thelen et al., 2017; Rabanal-Ruiz & Korolchuk, 2018). Searching for lysosomal terms in gene ontology and protein databases resulted in the identification of at least 500 proteins (Mi et al., 2019; The UniProt Consortium, 2019).

However, this approach is associated with important challenges related to the limited sensitivity of technologies in detecting low abundance proteins in lysosomes, lack of spatial information about the localization of the identified proteins in whole-cell analysis, and interaction with other organelles. In recent years, methods to reduce the biomolecular complexity of a sample by isolation and purification of individual cellular organelles have been developed (Diettrich et al., 1998; Chen et al., 2005; Walker & Lloyd-Evans, 2015; Tharkeshwar et al., 2017). These methods include density gradient centrifugation of cellular or tissue homogenates, use of magnetic iron oxide (FeO)-coated high-molecular-weight dextran particles to purify lysosomes from mammalian cells (Diettrich et al., 1998; Chen et al., 2005), and delivery of superparamagnetic iron oxide nanoparticles (SPIOs) to lysosomes by endocytosis (Walker & Lloyd-Evans, 2015). In this regard, it is important to mention the importance of the protein localization database based on careful subcellular localization studies combined with MS analysis (Prolocate, http://prolocate.cabm.rutgers.edu). More recent approaches are based on immunoaffinity enrichment of lysosomes from cells expressing a lysosomal transmembrane protein (i.e., TMEM192) fused to three tandem human influenza virus hemagglutinin (HA) epitopes using an antibody against HA conjugated to magnetic beads (Abu-Remaileh et al., 2017; Wyatt et al., 2018). This method is rapid at extracting highly pure lysosomes and may represent an important advance in the analysis of the lysosomal proteome and in the quantitative profiling of metabolites derived from the action of lysosomal enzymes or from the activity of lysosomal transporters under various cell states (Abu-Remaileh et al., 2017).

Changes in the amounts of specific metabolites within the lysosome might uncover novel aspects involved in the pathophysiology of complex LSD and lead to the identification of aberrant accumulation of specific cargo or metabolites that could be used as biomarkers to test the efficacy of novel therapies.

**How defects of lysosomal functions lead to disease**

Historically, the pathology and the clinical manifestations of lysosomal disorders have been considered as direct consequences of the storage of inert substrates in tissues.

Indeed, manifestations such as visceromegaly, skin thickness, skeletal dysmorphisms, and ocular signs (corneal opacities, cherry-red spot) might easily be viewed as the results of excessive undegraded substrates in cells and extracellular matrix.

This concept has been questioned by the new vision of lysosomal functions. Given the central role of lysosomes in cellular homeostasis and metabolism, it has been speculated that storage is just the “instigator” of a number of secondary events (Clarke, 2011) and that accumulation of undegraded substrates is able to prime complex pathogenetic cascades that are in fact responsible for LSD manifestations. Multiple and diverse events are now emerging as players in the pathogenesis of LSDs. Specifically, these events include storage of secondary substrates unrelated to the defective enzyme, abnormal composition of membranes and aberrant fusion and intracellular trafficking of vesicles, altered autophagic flux and accumulation of autophagic substrates, dysregulation of signaling...
pathways and activation of inflammation, abnormalities of calcium homeostasis, mitochondrial dysfunction, and oxidative stress (Ballabio & Gieselmann, 2009; Platt et al., 2018) (Fig 3).

Secondary storage

Secondary storage of unrelated and heterogeneous substrates has been extensively documented in several LSDs. For example, in mucopolysaccharidoses types I, II, IIIA, VI, and VII, characterized by primary storage of glycosaminoglycans, biochemical analysis of brain has shown that gangliosides GM2 and GM3 are also consistently and substantially elevated (Walkley & Vanier, 2009). Accumulation of GM2 and GM3 gangliosides has also been documented in a variety of other LSDs, including Niemann-Pick type A and type C1 (Zervas, et al., 2001), mucolipidosis type IV (Micsenyi et al., 2009) neuronal ceroid lipofuscinoses (Jabs et al., 2008), and alpha-mannosidosis (Goodman et al., 1991).

Secondary storage is thought to have a substantial role in the pathophysiology of LSDs. This idea is supported by the finding that secondary substrates localize in the brain areas that are most affected by the disease pathology (Tobias et al., 2019; Viana, et al., 2020) and that depletion of secondary substrates in experimental conditions (e.g., GM3 in the Niemann-Pick type C1 mouse model) results in amelioration of neuropathology and disease manifestations (Lee et al., 2014). Secondary storage may also impair vesicle trafficking. Cholesterol and other lipids, for example, have been shown to impair the endo-lysosomal system (Sobo et al., 2007; Walkley & Vanier, 2009), and the function of soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) (Fraldi et al., 2010; Sambri et al., 2017), which are critical for the fusion of cellular membranes (Lang et al., 2001).

These effects are not only limited to lysosomes but also implicated in the accumulation in other compartments of toxic storage materials, including multiple aggregate-prone proteins, α-synuclein, prion protein, Tau, amyloid β, and damaged mitochondria (Fraldi et al., 2016) that are known to be associated with common neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s disease. Alpha-synuclein accumulation has been found in several LSDs (Settembre et al., 2008a; Shachar et al., 2011; Di Malta et al., 2012) and suggests a link between alpha-synuclein aggregation toxicity and neurodegeneration in LSDs. Extensive work has been done about beta-glucocerebrosidase deficiency as a risk factor for the development of Parkinsonism (Aharon-Peretz et al., 2004; Gan-Or et al., 2008; Blanz & Saftig, 2016).

Impairment of autophagy

As lysosomes are the terminal compartment of the ALP, a general impairment of this pathway and of its critical functions in cell homeostasis is an obvious and expected finding in LSDs. A block of
Autophagy was initially recognized in a few of these disorders, namely in mucopolysaccharidosis type IIIA and in MSD (Settembre et al., 2008a), as well as in Pompe disease in which the accumulation of large pools of autophagic debris is a typical and consistent feature of skeletal muscle pathology (Fukuda et al., 2006a; Shea & Raben, 2009) and appears to be associated with dysregulation of mTORC1 and AMPK signaling (Lim et al., 2017).

Autophagic vesicle accumulation, together with increased polyubiquitinated proteins and dysfunctional mitochondria, has now been reported also in several other LSDs, such as some mucopolysaccharidoses, sphingolipidoses (Gaucher and Fabry disease, Niemann-Pick type C), mucolipidoses (type II, III and IV), Danon disease, and some neuronal ceroid lipofuscinoses (CLN 3, 10) (Liebermann et al., 2012).

The impairment of autophagy has important and deleterious consequences and is thought to contribute substantially to LSD pathophysiology. In Pompe disease, for example, the presence of autophagic accumulation was shown to impair the contractile function of muscles (Drost et al., 2005) and to affect the trafficking of recombinant enzymes used for enzyme replacement therapy (Fukuda et al., 2006b).

In neurons, a dysfunction of the ALP is thought to be involved in the pathophysiology of neurodegeneration (Hara et al., 2006; Komatsu et al., 2006; Monaco et al., 2020). The impairment of the ALP has also been shown to affect extracellular matrix formation and skeletal development and growth in chondrocytes from the mouse model of MPS VII (Bartolomeo et al., 2017; Settembre et al., 2018).

**Mitochondrial dysfunction**

One of the primary functions of autophagy is to execute mitochondrial turnover (Plotegher & Duchen, 2017; Wang & Wang, 2019). Thus, it is not surprising that mitochondrial dysfunction is emerging as an important player in the pathophysiology of LSDs. Substantial evidence supports the existence of a crosstalk and reciprocal functional relationships between mitochondria and lysosomes (Pshezhetsky, 2015). While defective autophagy affects mitochondrial quality control pathways and causes accumulation of damaged mitochondria, in turn mitochondrial dysfunction can impair lysosomal functions, such as acidification by the acidic pump V-ATPase that relies on the ATP generated by mitochondria (Stepien et al., 2020).

Perturbations in mitochondrial function and homeostasis have been recognized in several LSDs, including sphingolipidoses (Gaucher disease, Niemann-Pick disease type C, Krabbe disease), gangliosidoses, some mucopolysaccharidoses, multiple sulfatase deficiency, and neuronal ceroid lipofuscinoses (Plotegher & Duchen, 2017; Stepien et al., 2020) and have been proposed as one of the mechanisms underlying neurodegeneration (Martins et al., 2015; Saffari et al., 2017; Anunnziata et al., 2018).

Multiple mitochondrial defects were found in the mouse model of Pompe disease, including mitochondrial calcium excess, increased reactive oxygen species, decreased mitochondrial membrane potential, and decreased oxygen consumption and ATP production (Lim et al., 2015). Increased oxidative stress, elevation of reactive oxygen species (ROS), and enhanced susceptibility of cells to mitochondria-mediated apoptotic insults are obvious consequences of defects in mitophagy and mitochondrial dysfunction (Filomeni et al., 2015). Oxidative stress was observed in animal models of mucopolysaccharidoses type IIIB (Villani et al., 2009), type I (Donida et al., 2015), and type IIIA (Arfi et al., 2011) and in blood samples from patients affected by mucopolysaccharidoses types I (Pereira et al., 2008) and type II (Filippon et al., 2011).

**Alteration of signaling pathways and inflammation**

Non-physiologic activation of signal transduction pathways by storage compounds is another consequence of storage in LSDs. Stored materials may interfere with normal ligand–receptor interactions, modify receptor responses, influence internalization and recycling of receptors, and lead to altered activation of signaling pathways involved in cellular transport and vesicle trafficking, calcium homeostasis, oxidative stress, morphogen signaling, inflammatory and innate immune responses, and cell death (von Zastrow & Sorkin, 2007; Ballabio & Gieselman, 2009; Fiorenza et al., 2018; Platt et al., 2018).

Neuroinflammation and bone involvement are paradigm examples of manifestations related to altered signaling. Neuroinflammation has been reported in a large variety of LSDs, such as mucopolysaccharidoses (Zalfa et al., 2016; Viana et al., 2020; Heon-Roberts et al., 2020), sphingolipidoses (Potter & Petryniak, 2016; Fiorenza et al., 2018; Cougnoux et al., 2019), neuronal ceroid lipofuscinoses (Groh et al., 2016), and gangliosidoses (Utz et al., 2015). In some mucopolysaccharidoses, it has been shown that structurally anomalous glycosaminoglycans may mimic lipopolysaccharide, an endotoxin of gram-negative bacteria, and activate the Toll-like receptor 4 (TLR4) innate immune responses. As a consequence of TLR4 activation, secretion of proinflammatory cytokines increases together with the activation of tumor necrosis factor (TNF)-alpha (Simonaro et al., 2010; Parker & Bigger, 2019). Furthermore, the activation of an atypical pattern of interferon downstream signaling, involving both interferon (IFN)-gamma- and IFN-alpha-responsive genes, was detected in the cerebellum of the Niemann-Pick disease type C1 mouse model, resulting in the elevation of IFN-gamma-responsive cytokines (Shin et al., 2019).

Interestingly, aberrant morphogen signaling has emerged as a possible mechanism that may explain some clinical features of LSDs, such as skeletal dysmorphisms, traditionally viewed as a direct consequence of substrate accumulation (Fiorenza et al., 2018). For example, excess of accumulated glycosaminoglycans and defective proteoglycan desulphation have been shown to alter fibroblast growth factors-2 (FGF2)-heparan sulfate interactions and the FGF2 signaling pathway in a murine model of MSD (Settembre et al., 2008b), and bone morphogenetic protein (BMP)-4 signaling activity in mucopolysaccharidosis type I cells (Pan et al., 2005).

Altered FGF2 and Indian hedgehog distribution and impaired FGF2 signaling have been observed in growth plates from mucopolysaccharidosis type I mice (Kingma et al., 2016). In a zebrafish model of mucopolysaccharidosis type II, perturbations of glycosaminoglycan catabolism were associated with aberrant distribution and signaling of morphogens, such as sonic hedgehog (Shh), dysregulation of the Shh and Wnt/b-catenin signaling, and aberrant heart development and atriointerventional valve formation (Costa et al., 2017).

Shh dysregulation, with severely disturbed subcellular localization of the Shh effectors Patched (Ptc) and Smootherened (Smo), and of ciliary proteins were found in Niemann-Pick disease type C1
mice. Dysregulation of Shh signaling has been associated with shortening of primary cilium length and reduction in ciliated cells in animal brains and was proposed as a mechanism underlying abnormal cerebellum morphogenesis in this mouse model (Canterini et al., 2017; Formichi et al., 2018).

Abnormalities of Ca²⁺ signaling are thought to play an important role in LSDs (Lloyd-Evans & Waller-Evans, 2019; Liu & Lieberman, 2019). The importance of this signaling pathway for LSD pathophysiology was revealed by mucolipidosis type IV. This disorder is due to mutations in the mucolipin 1 (MCOLN1) gene that encodes the lysosomal Ca²⁺-releasing channel TRPML1. Mucolipidosis IV pathology is the consequence of defective TRPML1 function and aberrant Ca²⁺ signaling, and is characterized by impaired vesicle trafficking and extensive storage of granular material and lamellar and concentric bodies (LaPlante et al., 2004). Ca²⁺ abnormalities have also been found in other LSDs and thought to participate in disease pathophysiology. In Niemann-Pick type C1 mutant cells, for example, remarkable reduction in the acidic compartment calcium stores was observed, compared to wild-type cells, likely due to sphingosine storage that induces calcium depletion in lysosomes, possibly through an inhibitory effect on Na⁺/Ca²⁺ exchangers (Lloyd-Evans et al., 2008; Lloyd-Evans & Platt, 2011).

### Current and future therapies

#### Enzyme replacement therapy

Given that the majority of LSDs are due to the deficiency of a lysosomal hydrolase, the primary approach, and the first to be explored, was based on replacing the defective activity with a wild-type functional enzyme. This strategy was pursued through hematopoietic stem cell transplantation and enzyme replacement therapy (ERT), which are based on the concept that lysosomal enzymes can be taken up by cells and correctly delivered to lysosomes through the mannose-6-phosphate pathway.

After the pioneering studies in Gaucher disease (Barton et al., 1990; Barton et al., 1991) that demonstrated the feasibility and the efficacy of ERT in the non-neuropathic forms of this disorder, this approach is currently considered the standard treatment for several LSDs, including the most prevalent of these disorders, such as Gaucher disease, Fabry disease, Pompe disease, some mucopolysaccharidoses, and a few ultra-rare disorders (e.g., lysosomal acid lipase deficiency, mucopolysaccharidosis type VII) and is in clinical development for others (Platt et al., 2018; Poswar et al., 2019). However, despite remarkable success in treating some aspects of LSDs, we have learned from the experience of many years that ERT has limitations. Recombinant enzymes are immunogenic and may induce immune responses, particularly in cross-reactive immunologic material (CRIM)-negative patients (Berrier et al., 2015). Development of antibodies against the therapeutic enzyme may impact on the efficacy of therapies or cause immune-mediated severe adverse reactions that require laborious and expensive protocols for induction of immune tolerance (Desai et al., 2019). ERT is based on periodic infusions, often requiring the use of intra-venous devices that are associated with risk of life-threatening infections. Thus, the impact on the quality of life of patients and their caregivers is substantial (Wyatt et al., 2012; Platt, 2018). In addition, costs of therapies are high and represent an economical burden for healthcare systems (Wyatt et al., 2012).

An additional and major issue is the insufficient biodistribution of the recombinant enzymes used for ERT, leading to inability to reach therapeutic concentrations in specific tissues. Recombinant enzymes are large molecules, often unable to cross anatomical and functional barriers. In several LSDs, the main target tissues, where the correction of enzyme activity is required to clear storage and improve pathology, are in fact the most difficult to reach (van Gelder et al., 2012). For these reasons, second-generation recombinant enzymes with improved targeting properties or pharmacodynamics are currently under development, for example, avalglucosidase-apha, a glycoengineered GAA, for the treatment of Pompe disease (Pena et al., 2019; Xu et al., 2019) and pegunigalsidase alfa, a PEGylated covalently cross-linked alpha-galactosidase A, for the treatment of Fabry disease (Schiffmann et al., 2019).

The inability of recombinant enzymes to cross the blood–brain barrier has major clinical relevance, as the majority of LSDs can be associated with neurological manifestations. Intrathecal or intraventricular delivery of enzyme has been proposed for some mucopolysaccharidoses (Giugliani et al., 2018), metachromatic leukodystrophy (I Dalí et al., 2020), and is now an approved treatment for neuronal ceroid lipofuscinosis 2, in which intraventricular infusions of cerliponase-alpha reduced disease progression (Schulz et al., 2018). The use of chimeric lysosomal enzymes, in which the therapeutic enzyme is conjugated with different peptides or antibody components that exploit interactions with specific receptors and mediate transport across the blood–brain barrier, is also a strategy that is currently being investigated (Sonoda et al., 2018; Pardridge et al., 2018; Yagalingam et al., 2019).

#### Pharmacological therapy

Indeed, LSDs have proven to be an extraordinary field of investigation with the development of multiple and diverse therapeutic strategies that hit different targets in the pathogenetic cascade of these disorders (Cox, 2015).

One of these strategies was aimed to restore the equilibrium of the so-called “storage equation” (i.e., the balance between the amount of substrate that is delivered to lysosomes for degradation, and the amount of enzymes that are involved in its breakdown) by reducing flux of substrates to lysosomes with small-molecule inhibitors of substrate synthesis (substrate reduction therapy—SRT). The first of such compounds to be used was the imino sugar Miglustat (N-butyl-deoxynojirimicin), a reversible inhibitor of glucosylceramide synthase, that catalyzes the formation of glucocerebroside and thereby initiates the glycosphingolipid biosynthetic pathway (Pastores & Barnett, 2003). Miglustat showed efficacy in correcting some clinical and biochemical parameters in Gaucher disease patients (Cox, 2005; Charrow & Scott, 2015). For its effect on this early step of the glycosphingolipid biosynthetic pathway, Miglustat has also been proposed for the treatment of GM1 and GM2 gangliosidoses, with a slowed disease progression (Poswar et al., 2019; Fischetto et al., 2020), and is approved for the treatment Niemann-Pick disease type in, in which gangliosides GM2, GM3 gangliosides, and other glycosphingolipids play a role in the pathogenesis of neurological manifestations (Zervas et al., 2001). Other substrate-reducing molecules are now in clinical development or approved for the treatment of Gaucher and Fabry disease, such as eliglustat tartrate, venglustat,
and lucerastat (Felis et al, 2019; Poswar et al, 2019). This approach is attractive, as substrate-reducing drugs are small molecules that reach therapeutic concentrations in tissues, including those that are difficult to reach by ERT, and can be taken orally, with minimal impact on patient quality of life.

Newer approaches, based on different strategies, are now in a phase of advanced development. In most cases, they are also aimed at increasing or replacing the defective enzyme activity. Pharmacological chaperone therapy (PCT) is based on the use of small-molecule drugs that enhance the stability of mutant enzyme proteins with residual activity, through specific non-covalent interactions with the target enzymes, thus favoring their trafficking to lysosomes (Parenti et al, 2015).

PCT is now approved for the treatment of patients affected by Fabry disease. Migalastat (1-deoxygalactonojirimycin), an active site-directed amino sugar reversible inhibitor of alpha-galactosidase A, was shown to paradoxically rescue the activity and the stability of this enzyme in cells from Fabry disease patients, opening the way to further development of this approach (Fan et al, 1999). This compound has shown clinical efficacy on different clinical manifestations of Fabry disease (Germain et al, 2016; Hughes et al, 2017; Lenders et al, 2020) and is now approved for the treatment of patients with amenable GLA gene mutations. PCT has evident advantages compared with ERT, as chaperones are small-molecule drugs that can be taken orally by patients and are expected to penetrate across membranes and physiological barriers, thus reaching therapeutic concentrations in multiple tissues. On the other hand, a major limitation of this approach is the possibility to treat only patients carrying specific mutations (Benjamin et al, 2017). Concerns on the use of PCT have also been raised as chaperones interact with the catalytic sites and are thus reversible competitive inhibitors of their target enzymes. For the treatment of Fabry disease, this risk has been eluded using a protocol based on discontinuous, every other day administration (Germain et al, 2016), taking advantage of the short half-life of the drug compared with that of alpha-galactosidase A. New, allosteric drugs that interact with non-catalytic domains of the enzyme and are thus non-inhibitory may represent an alternative strategy to minimize the risk of unwanted enzyme inhibition (Porto et al, 2012; Parenti et al, 2015a).

The use of proteostasis modulators has also been proposed to rescue mutant, unstable lysosomal enzymes (Mu et al, 2008; Fog et al, 2018; Seemann et al, 2020). However, the drugs used for this approach are non-specific and may be associated with significant adverse effects.

The demonstration of a synergy between PCT and ERT attracted further interest on this approach. This effect was first demonstrated in vitro and in vivo in cells from patients with Pompe disease and in the murine model of this disease (Porto et al, 2009; Khanna et al, 2012). This synergy was translated into clinical trials (Parenti et al, 2014; Kishnani et al, 2017) and is now under further clinical development (Data ref: ClinicalTrials.gov NCT04138277). The advantage of this synergy, compared with the “traditional” use of chaperones, is that the effect of the drug is directed toward the recombinant enzyme used for ERT, and not to the endogenous mutant enzyme. Thus, the effect of chaperones with this approach is mutation-independent and can in principle be extended to all patients on ERT. Also, the administration of the chaperone is limited to the time of the ERT infusion (e.g., every other week in Pompe disease), with less risk of undesired effects of the drug.

**Gene therapy**

Gene therapy holds great promise and is under advanced clinical development for several LSDs. The approaches used so far for gene therapy of LSDs are based both on the use of adeno-associated viral (AAV) vectors in vitro and of lentiviral vectors ex vivo. AAV-mediated in vivo gene transfer is based on injection of a vector carrying the transgene under the control of ubiquitous or organ-specific promoters. Ex vivo gene therapy is based on the correction of patient’s cells, such as hematopoietic stem cells, followed by genetic modification in vitro and re-implantation in the patients of the modified cells. Both approaches imply both local correction of a target tissue/organ and cross-correction of distant tissues/organs by secreted enzymes that are internalized through the mannose-6-phosphate receptor pathway (Sands & Davidson, 2006).

Quite encouraging results have been obtained using the ex vivo approach in metachromatic leukodystrophy (Biffi et al, 2013; Sessa et al, 2016). Patients treated early showed improved course or complete prevention of disease manifestations, associated with improved brain MRI scores. In vivo AAV-mediated gene therapy studies have been completed (Corti et al, 2017) or are in progress.

However, like for ERT, important challenges remain to be faced also by gene therapy, particularly the need for sustained expression of the therapeutic enzyme, and the need for correction of neuropathology. To address this latter issue, studies aimed at correcting brain involvement through direct intraparenchymal or intrathecal vector administration have been performed for the treatment of mucopolysaccharidosis types II A and II B (Tardieu et al, 2014; Tardieu et al, 2017).

Other approaches based on gene editing for mucopolysaccharidosis types I and II (Data ref: ClinicalTrials.gov NCT03041324), inhibition of nonsense-mediated decay and translational read-through (Banning et al, 2018), and messenger RNA (mRNA) therapy (an approach based on biosynthetic mRNA transcripts to drive the synthesis of therapeutic proteins) (Zhu et al, 2019) are under evaluation.

Other strategies that are currently under investigation are based on the use of antisense oligonucleotides that allow for rescue of the normal splicing of transcripts. For example, this approach appears to particularly attractive for the treatment of late-onset Pompe disease patients, in which a c.-32-13T > C mutation causes aberrant splicing and exon 2 partial or complete skipping with reduced synthesis of normal mRNA. This variant is highly prevalent (40–70% of alleles). Thus, a therapy for this mutation would have the advantage of being effective in a large fraction of patients. The characterization of splicing regulatory elements in GAA intron 1 and exon 2 and of the effects of the c.510C > T variant that modulates the effects of the c.-32-13T > C mutation (Bergsma et al, 2019) helped developing an antisense oligonucleotide-based approach to promote exon 2 inclusion and enhanced GAA enzyme activity to levels above the disease threshold (van der Wal, 2017). Preliminary in vitro data show promising rescue of acid alpha glucosidase activity in cells from Pompe patients by using this approach (Goina et al, 2017; van der Wal, 2017).
Pending Issues

The current understanding of lysosome biology and function is still evolving. There is a need for further characterization of these aspects that may provide critical information on the pathophysiology of lysosomal storage diseases. New methodologies should be exploited to improve our knowledge on lysosomal biology and on lysosomal disease pathophysiology. These methodologies may also have a major impact of patient care, with more efficient diagnostic pathways and availability of biomarkers to follow disease progression and effects of therapies. Current therapies for the treatment of lysosomal storage disease have significant limitations. Particularly, biodistribution in target organs, such as brain, is a critical issue as many of these disorders are associated with central nervous system involvement. The understanding of disease pathophysiology is critical as it has the potential to identify novel therapeutic targets and to indicate new strategies for the treatment of these disorders.

Adjuvant therapies

In view of the emerging complexity of LSD pathophysiology, novel strategies are being explored that are based on an entirely different rationale and may represent adjunctive approaches to the treatment of LSDs. These approaches are not directed toward correction of the enzymatic defects and the causative gene mutations, or on modulation of the flux of substrates to lysosomes, but they are rather targeted to the manipulation of the pathways that are secondarily altered in LSDs.

For example, the abnormalities of the autophagic pathway are attractive targets. Indeed, manipulation of this pathway has been proposed as a therapeutic strategy for Pompe disease, providing some evidence of efficacy. In vitro and in vivo overexpression of TFEB also induced exocytosis, enhanced glycogen clearance, and resulted in some improvements in physical performance of Pompe disease mice (Spampanato et al., 2013; Gatto et al., 2017). In vitro overexpression of TFE3 triggered lysosomal exocytosis and resulted in efficient cellular clearance (Martina et al., 2014). This approach that has been explored so far through overexpression of master genes controlling the autophagic pathway may be difficult to translate into clinical applications. However, based on these proof-of-concept studies, alternative strategies based on the search for small-molecule drugs modulating autophagy may be envisaged, with a better potential for clinical translation.

Aberrant activation inflammation is another potential therapeutic target. For example, as neuroinflammation has been documented in several LSDs, the pathways that are involved in the activation of the inflammasome are now being considered as additional potential therapeutic targets. Pentosan polysulfate, a mixture of semisynthetic sulfated polyanions, has been shown to have anti-inflammatory effects in some LSDs, in particular targeting the activation TLR4 and the consequent secretion of proinflammatory cytokines and tumor necrosis factor (TNF)-α. This drug has been tested in mucopolysaccharidosis type I and II patients and in animal models of mucopolysaccharidosis types I, IIA, and VI (Simonaro et al., 2010; Simonaro et al., 2016; Orii et al., 2019), and in in vitro models of Fabry and Gaucher disease (Crivaro et al., 2019). Intraperitoneal high-dose aspirin reduced neuroinflammation in mucopolysaccharidosis type IIIB mice, with significantly reduced transcript levels of MIP-1α, IL-1β, and GFAP (Arfi et al., 2011). A combination of Miglustat as a substrate-reducing agent, the Ca2+-modulator curcumin, and a non-steroidal anti-inflammatory drug to target inflammation was evaluated in Niemann-Pick disease type C1 mice and resulted into maintained body weight and motor function, reduced microglial activation, and delayed onset of Purkinje cell loss (Williams et al., 2014).

Other experimental therapeutic approaches have been directed toward correction of intralysosomal calcium levels in Niemann-Pick disease type C1 (Lloyd-Evans et al., 2008) and reduction in oxidative stress in Krabbe disease (Hawkins-Salsbury et al., 2012), while stimulation of the cytoprotective effect of HSP70 with the small-molecule arimoclomol in Niemann-Pick disease type C1 is under clinical evaluation (Kirkegaard et al., 2016).

Although these approaches directed toward correction of the secondary abnormalities in LSDs are not expected to be curative, they may be of help in improving quality of life and slow disease progression. It is possible to speculate that correction of these abnormalities may synergize with existing therapies. For example, in Pompe disease the block of autophagy has been shown to impact on the lysosomal trafficking of the recombinant enzyme used for ERT (Fukuda et al., 2006b). It may be conceivable that improving the status of autophagic pathways may translate into improved lysosomal delivery of the therapeutic enzyme.

It is possible that other potential therapeutic targets will be identified thanks to the precise characterization of the pathogenetic cascade of LSDs and will open new avenues to the treatment of LSDs.

Acknowledgements

This work was supported by grants from the Italian Telethon Foundation (TGM16CB6); MIUR FIRB RBAP11Z3YA (A.B.); European Research Council Advanced Investigator no. 694282 (LYSOSOMICS) (A.B.); U.S. National Institutes of Health (R01-NS078072) (A.B.); the Huffington Foundation (A.B.); the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) (A.B.); European Regional Development Fund—POR Campania FESR 2014/2020; (IG 2015 id17639 and (PPDF) (MCO 10000 and IG 18988 to PPDF); and the Italian Ministry of Health (PPDF) (RF-2016-02361540). This manuscript is dedicated to the memory of Thomas Dierks, Bielefeld University, Germany.

Conflict of interest

A. Ballabio is co-founder of CASMA Therapeutics and of Next Generation Diagnostics (NGD).

For more information

- NORD—National Association for rare diseases: https://rarediseases.org/rare-diseases/lysosomal-storage-disorders/
- Lysosomal Disease Network Patients & Families: https://lysosomaldiseasenetwork.org/
- National Gaucher Foundation: https://www.gaucherdisease.org/
- National Fabry Disease Foundation: https://www.fabrydisease.org/
- Sanfilippo Children Association: https://www.sanfilippo.org.au/
- Acid Maltase Deficiency Association: https://amda-pompe.org/
- European Reference Network for Hereditary Metabolic Disorders: https://metabolnet.eu/
- Tigern—The Telethon Institute of Genetics and Medicine: https://www.tigem.it/
- Telethon Foundation: https://www.telethon.it/
References

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects with LOPD (2019) ClinicalTrials.Gov NCT04138277 (https://clinicaltrials.gov/ct2/show/NCT04138277) [DATASET]

Abu-Reemal-Me M, Wyant GA, Kim C, Laqtom NN, Abbasi M, Chan SH, Freinmann E, Sabatinui DM (2017) Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358: 807 – 813

Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351: 1972 – 1977

Anderson S (2018) Newborn screening for lysosomal storage disorders. J Pediatr Health Care 32: 285 – 294

Anunniata I, Sano R, d’Azzo A (2018) Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. Cell Death Dis 9: 328

Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Theron P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 103: 18 – 25

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) (2017) NCT03041324 [https://clinicaltrials.gov/ct2/show/NCT03041324] [DATASET]

Ballabio A, Gieselmann V (2017) Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358: 807 – 813

Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351: 1972 – 1977

Anderson S (2018) Newborn screening for lysosomal storage disorders. J Pediatr Health Care 32: 285 – 294

Anunniata I, Sano R, d’Azzo A (2018) Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. Cell Death Dis 9: 328

Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Theron P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 103: 18 – 25

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) (2017) NCT03041324 [https://clinicaltrials.gov/ct2/show/NCT03041324] [DATASET]

Ballabio A, Gieselmann V (2009) Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 179: 684 – 696

Ballabio A, Bonifacio JS (2020) Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol 21: 101 – 138

Banning A, Schiff M, Tikkanen R (2018) Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria. Biochim Biophys Acta Mol Basis Dis 1864: 668 – 675

Bartolomeo R, Cinque L, De Leonibus C, Forrester A, Salzano AC, Monfregola J, De Gennaro N, Nusco E, Aizari I, Lanarra C et al (2017) mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy. J Clin Invest 127: 3717 – 3729

Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Prot Natl Acad Sci USA 87: 1913 – 1916

Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mamin H, Murray GJ, Parker RI, Argoff CE et al (1991) Replacement therapy for inherited enzyme deficiency-macrophase-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324: 1464 – 1470

Beck M (2001) Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis 24: Suppl 2: 47 – 51

Bellomo F, Medina DL, De Leo E, Panarella A, Emma F (2017) High-content drug screening for rare diseases. J Inherit Metab Dis 40: 601 – 607

Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG et al (2017) The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 19: 430 – 438

Bergsma AJ, In’t Groen SLM, van den Dorpel JJA, van den Hout HJMP, van der Beek NAME, Schoorser B, Toscano A, Musumeci O, Bembi B, Dardis A et al (2019) A genetic modifier of symptom onset in Pompe disease. Elife 8: 2289

Berger KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanesku MC, Rehder CW, Botha EG, Elawey C, Bhattacharya K et al (2015) CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med 17: 912 – 918

Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martinu S, Calabria A, Canale S et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158

Blanz J, Saftig P (2016) Parkinson’s disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J Neurochem 139(Suppl 1): 198 – 215

Boutin M, Aury-Blais C (2015) Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers. J Am Soc Mass Spectrom. 26: 499 – 510

Burlina AB, Polo G, Salvati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zorden X et al (2018) Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis 41: 209 – 219

Calgieni A, Kors L, Verschuren E, De Cegli R, Zampelli N, Nusco E, Confalonieri S, Bertalot G, Pece S, Settembre C et al (2016) Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. Elife 5: e17047

Cammarata G, Scala S, Colomba P, Zizzo C, Pisani A, Riccio E, Montalbano M, Alessandro R, Giordano A, Duro G (2018) A pilot study of circulating microRNAs as potential biomarkers of Fabry disease. Oncotarget 9: 27333 – 27345

Canteneri S, Dragotto J, Dardis A, Zampieri S, De Stefano ME, Mangia F, Erickson RP, Fiorella MT (2017) Shortened primary cilia length and dysregulated Sonic hedgehog signaling in Niemann-Pick C1 disease. Hum Mol Genet. 26: 2277 – 2289

Carrasco-Rozas A, Fernandez-Simon E, Lleixà MC, Belmonte I, Pedrosa-Hernandez I, Montiel-Morillo E, Nuñez-Peralta C, Llauger Rossello C, Segovia S, De Luca N et al (2019) Identification of serum microRNAs as potential biomarkers in Pompe disease. Ann Clin Transl Neurol 6: 1214 – 1224

Chapel A, Kieffer-Jauninod S, Sagné C, Verdon Q, Ivaldi C, Mellal M, Thirion J, Kodad M, Bruley C, Garin et al (2013) An extended proteome map of the lysosomal membrane reveals novel potential transporters. Mol Cell Proteomics 12: 1572 – 1588

Charrow J, Scott CR (2015) Long-term treatment outcomes in Gaucher disease. Am J Hematol 90(Suppl 1): S19 – 24

Chatcheri S, Ahn EH, Kim DH (2017) CRISPR genome engineering for human pluripotent stem cell research. Theranostics: 7: 4445 – 4469

Chen FW, Gordon RE, Ioannou YA (2005) NPC1 late endosomes contain elevated levels of non-esterified (‘free’) fatty acids and an abnormally glycosylated form of the NPC2 protein. Biochem J 390: 549 – 561

Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai F et al (2009) Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 124: e1116 – e1125

Christensen KA, Myers JT, Swanson JA (2002) pH-dependent regulation of lysosomal calcium in macrophages. J Cell Sci 115: 599 – 607

Cinque L, Forrester A, Bartolomeo R, Svelto M, Venditti R, Montefusco S, Polischuk E, Nusco E, Rossi A, Medina DL et al (2015) FGF signalling regulates bone growth through autophagy. Nature 528: 272 – 275

Clarke LA (2011) Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology 50(Suppl 5): v13 – v18

Cologna SM, Jiang XS, Backlund PS, Cluzeau CV, Dail MK, Yanjanim NM, Siebel S, Toth CL, Jun HS, Wassf CA et al (2012) Quantitative proteomic analysis of Niemann-Pick disease type C1 cerebellum identifies protein biomarkers and provides pathological insight. PLoS One 7: e47845

Corti M, Liberati C, Smith BK, Lawson LA, Tuna S, Conlon TJ, Coleman KE, Islam S, Herzog RW, Fuller DD et al (2017) Safety of intraphagocytic
delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev 28: 208 – 218

Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A (2003) The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113: 445 – 456

Costa R, Urbani A, Salvaioia M, Bellesso S, Cieri D, Zancan I, Filacamo M, Bonaldo P, Szabo I, Tomanin R et al (2017) Perturbations in cell signaling elicit early cardiac defects in mucopolysaccharidosis type II. Hum Mol Genet 26: 1643 – 1655

Costanzo M, Zacchia M, Bruno G, Crisci D, Caterino M, Ruoppolo M (2017) Integration of proteomics and metabolomics in exploring genetic and rare metabolic diseases. Kidney Dis 3: 66 – 77

Cougnoux A, Drummond RA, Fellmeth M, Navid F, Collar AL, Iben J, Kulkarni AB, Pickel J, Schiffrnan R, Wassif CA et al (2019) Unique molecular signature in mucolipidosis type IV microglia. J Neuroinflammation 16: 276

Cox TM (2005) Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl 94: 57 – 69

Cox TM (2015) Innovative treatments for lysosomal diseases. Best Pract Res Clin Endocrinol Metab 29: 275 – 311

Crivaro AN, Mucci JM, Bondar CM, Ormazabal ME, Ceci R, Simonaro C, Rozenfeld PA (2019) Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1/2 clinical trial. Mol Genet Metab 16: 30152 – 30159

Dasgupta N, Xu YH, Oh S, Sun Y, Jia L, Keddache M, Grabowski GA (2013) Gaucher disease: transcriptome analyses using microarray or miRNA sequencing in a Gba1 knockout mouse model treated with velaglucerase alfa or imiglucerase. PLoS One 8: e74912

Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E (2017) Lysosomal proteome and secretome fractionation studies. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 60: 604 – 617

Desai AK, Li C, Rosenberg AS, Kishnani PS (2019) Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med: 7: 285

Dibble CC, Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25: 545 – 555

Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figure K (2003) Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 113: 435 – 444

Dietrich O, Mills K, Johnson AW, Hasilak A, Winchester BG (1998) Application of magnetic chromatography to the isolation of lysosomes from fibroblasts of patients with lysosomal storage disorders. FEBS Lett 441: 369 – 372

Di Fruscio G, Schulz A, De Cegli R, Savarese M, Mutarelli M, Parenti G, Banfi S, Braulik T, Negro V, Ballabio A (2015) Lysoplex: an efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway. Autophagy 11: 9289 – 9338

Di Lorenzo G, Velho RV, Winter D, Thelen M, Ahmadi S, Schweizer M, De Pace R, Cornils K, Yorgan TA, Crub S et al (2018) Lysosomal proteome and secretome analysis identifies missorted enzymes and their nondegraded substrates in mucopolysaccharidosis III mouse cells. Mol Cell Proteomics 17: 1612 – 1626

Di Malta C, Fyer JD, Settembre C, Ballabio A (2012) Autophagy in astrocytes: a novel culprit in lysosomal storage disorders. Autophagy 8: 1871 – 1872

Donati MA, Pasquini E, Spada M, Polo G, Burlina A (2018) Newborn screening in mucopolysaccharidoses. Ital J Pediatr 44(Suppl): 2: 126

Donida B, Marchetti DP, Biancini CB, Deon M, Manini PR, da Rosa HT, Moura DJ, Saffi J, Bender F, Burin MG et al (2015) Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochem Biophys Acta 1852: 1012 – 1019

Drost MR, Hesselink RP, Oomens CW, van der Vusse GJ (2005) Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 38: 1035 – 1043

Evers BM, Rodriguez-Navas C, Tesla RJ, Prange-Kiel J, Wasser CR, Yoo KS, McDonald J, Cenik B, Ravenscroft TA, Plattner F et al (2017) Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. Cell Rep 20: 2565 – 2574

Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112 – 115

Fan M, Sidhu R, Fujihara W, Tortelli B, Zhang J, Davidson C, Walkley SU, Bagel JH, Vite C, Yanjanin NM et al (2013) Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J Lipid Res 54: 2800 – 2814

Felix A, Whitlows M, Kraus A, Warnock DG, Wallace E (2019) Current and investigational therapeutics for fabry disease. Kidney Int Rep 5: 407 – 413

Filippion L, Vanzin CS, Biancini GB, Pereira IN, Manfredini V, Sitta A, Peralba Mdo C, Schwartz IV, Giugliani R, Vargas CR (2011) Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. Mol Genet Metab 103: 121 – 127

Filomeni G, De Zio D, Cecconi F (2015) Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ 22: 377 – 388

Finorezza MT, Moro E, Erickson RP (2018) The pathogenesis of lysosomal storage disorders: beyond the engorgement of lysosomes to abnormal development and neuroinflammation. Hum Mol Genet 27: R119 – R129

Fischetto R, Palladino V, Mancardi MM, Giacomini T, Palladino S, Gaeta A, Di Rocco M, Zampini L, Lassandro G, Favia V et al (2020) Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: a multicenter experience. Mol Genet Genomic Med 8: e1371

Fog CK, Zago P, Malini E, Solanko LM, Peruzzo P, Bonaes C, Magnoni R, Mehmmedbasic A, Petersen NHT, Bembi B et al (2018) The heat shock protein amplifier anirnocimol improves refolding, maturation and lysosomal activity of glucocerebrosidase. ElBioMedicine 38: 142 – 153

Formichi P, Battisti C, De Santi MM, Guazzo R, Trippodi SA, Radi E, Rossi B, Tarquini E, Federico A (2018) Primary cilium alterations and expression changes of Patched1 proteins in niemann-pick type C disease. J Cell Physiol 233: 663 – 672

Fraldi A, Annunziata F, Lombardi A, Kaiser HJ, Medina DL, Spampanato C, Fog CK, Zago P, Malini E, Solanko LM, Peruzzo P, Bonaes C, Magnoni R, Mehmmedbasic A, Petersen NHT, Bembi B et al (2018) The heat shock protein amplifier anirnocimol improves refolding, maturation and lysosomal activity of glucocerebrosidase. ElBioMedicine 38: 142 – 153

Fraldi A, Annunziata F, Lombardi A, Kaiser HJ, Medina DL, Spampanato C, Fedele AO, Polsichuk R, Sorrentino NC, Simons K et al (2010) Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J 29: 3607 – 3620

Fraldi A, Kleen AD, Medina DL, Settembre C (2016) Brain disorders due to lysosomal dysfunction. Annu Rev Neurosci 39: 277 – 295

Fu H, Meadows AS, Pineda RJ, Molney RP, Sturdivant S, McCarty DM (2017) Serum global metabolomics profiling reveals profound metabolic...
impairments in patients with MPS IIIA and MPS IIIB. Metab Brain Dis 32: 1403–1415

Fukuda T, Roberts A, Ahearn M, Zaal K, Raistone E, Plotz PH, Raben N (2006a) Autophagy and lysosomes in Pompe disease. Autophagy 2: 318 –320

Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, Raistone E, Plotz PH, Raben N (2006b) Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 14: 831 –839

Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD (1982) Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217: 1263 –1265

Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70: 2277–2283

Gatto F, Rossi B, Tarallo A, Polischuk E, Polischuk R, Carrella A, Nusco E, Alvino FG, Iacobellis F, De Leonibus E (2021) Incidence of 4 lysosomal storage disorders from 4 years of newborn screening. JAMA Pediatr. 172: 696 –697

Hicks M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet. 160: 59–68
Kumar AB, Hong X, Yi F, Wood T, Gelb MH (2019) Tandem mass spectrometry-based multiplex assays for α-mannosidosis and fucosidosis. Mol Genet Metab 127: 207 – 211
Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele R, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20: 2202 – 2213
LaPlante JM, Ye CP, Quinn SJ, Goldin E, Brown EM, Slaugenhaupt SA, Vassilev PM (2004) Functional links between mucolipin-1 and Ca2+-dependent membrane trafficking in mucolipidosis IV. Biochim Biophys Acta Comm 1721: 1384 – 1391
Lawrence RE, Fromm SA, Fu Y, Yokom AL, Kim DJ, Thelen AM, Young LN, Lim CY, Samelson AJ, Hurley JH et al (2019) Structural mechanism of a Rag GTPase activation checkpoint by the lysosomal folliculin complex. Science 366: 971 – 977
Lee H, Lee JK, Bae YC, Yang SH, Okino N, Schuchman EH, Yamashita T, Bae JS, Jin HK (2014) Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C by affecting sphingolipid metabolism. Mol Cells 37: 161 – 171
Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulia M, Müntze j, Üçeyler N et al (2020) Treatment of Fabry’s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther 108: 326 – 337
Lim JA, Li L, Kakhlon O, Myerowitz R, Raben N (2015) Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 11: 385 – 402
Lim JA, Li L, Shirihai OS, Trueude KM, Puertollano R, Raben N (2017) Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol Med 9: 353 – 370
Lojewski X, Staropoli PJ, Biswas-Legrand S, Simas AM, Haliw L, Selig MK, Coppel SH, Goss KA, Petcherski A, Chandrachud U et al (2014) Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TDP1 and CLN3 mutations on the endocytic pathway. Hum Mol Genet 23: 2005 – 2022
Lloyd-Evans E, Platt FM (2011) Lysosomal Ca(2+) homeostasis: role in pathogenesis of lysosomal storage diseases. Cell Calcium 50: 200 – 205
Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliott-Smith E, Silence DJ, Churchill GC, Schuchman EH, Galione A, Platt FM (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 14: 1247 – 1255
Lloyd-Evans E, Waller-Evans H (2019) Lysosomal Ca(2+)- Homeostasis and Signaling in Health and Disease. Cold Spring Harb Perspect Biol a035311.
Khurana V, Tardiff DF, Chung CY, Lindquist S (2015) Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat Rev Neurol 11: 339 – 350
Lieberman PA, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A (2012) Autophagy in lysosomal storage disorders. Autophagy 8: 719 – 730
Liu B, Palmfeidt J, Lin L, Colaço A, Clemmensen KKB, Huang J, Xu F, Liu X, Maeda K, Luo Y et al (2018) STAT3 associates with vacuolar H+-ATPase and regulates cytosolic and lysosomal pH. Cell Res 28: 996 – 1012
Liu EA, Lieberman AP (2019) The intersection of lysosomal and endoplasmic reticulum calcium with autophagy defects in lysosomal diseases. Neurosci Lett 697: 10 – 16
Lübke T, Lobel P, Sleat DE (2009) Proteomics of the lysosome. Biochim Biophys Acta 1793: 625 – 635
Lukacs Z, Nickel M, Murko S, Nieves Cobos P, Schulz A, Santer R, Kohlschütter A (2019) Validity of a rapid and simple fluorometric tripeptidyl peptidase I (TPP1) assay using dried blood specimens to diagnose CLN2 disease. Clin Chim Acta 492: 69 – 71
Maekawa M, Shimada M, Ohno K, Togawa M, Nittomo H, Iida T, Hofmann AF, Goto J, Yamaguchi H, Mano N (2015) Focused metabolomics using liquid chromatography/electrospray ionization tandem mass spectrometry for analysis of urinary conjugated cholesterol metabolites from patients with Niemann-Pick disease type C and 3β-hydroxysteroid dehydrogenase deficiency. Ann Clin Biochem 52: 576 – 587
Martina JA, Chen Y, Cucek M, Puertollano R (2012) MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 8: 903 – 914
Martina JA, Puertollano R (2013) RRAG GTPases link nutrient availability to gene expression, autophagy and lysosomal biogenesis. Autophagy 9: 928 – 930
Martina JA, Diab HI, Lishu L, Jeong-A L, Patange S, Raben N, Puertollano R (2014) The nutrient-responsive transcription factor TFEB promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal 7: ra9
Martin KB, Williams IM, Cluzeau CV, Cougnoux A, Dale RK, Iben JR, Cawley NX, Wassif CA, Porter FD (2019) Identification of novel pathways associated with patterned cerebellar purkinje neuron degeneration in niemann-pick disease, type CI. Int J Mol Sci 21: 292
Martins C, Hülková H, Drudi L, Dormoy-Raclet V, Grigoryeva L, Choi Y, Langford-Smith A, Wilkinson FL, Ohmi K, DiCristo G et al (2015) Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. Brain 138: 336 – 355
Matafaro V, Cuccurullo M, Beneducì A, Petruzziello O, Simeone A, Anastasio P, Mignani R, Ferozzi S, Pisani A, Comotti C et al (2015) Early markers of Fabry disease revealed by proteomics. Mol Biosyst 11: 1543 – 1551.
Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A et al (2015) Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol 17: 288 – 299
Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA et al (2006) Newborn screening for lysosomal disease. Mol Genet Metab 88: 307 – 314
Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U (2006) History of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol 17: 288 – 299
Micsenyi MC, Dobrenis K, Stepheigny G, Pickel J, Vanier MT, Slaugenhaupt SA, Walkley SU (2009) Neuropathology of the Mcn11c(-/-) knockout mouse model of mucolipidosis type IV. J Neuropathol Exp Neurol 68: 125 – 135
Monaco A, Maffia V, Sorrentino NC, Sambiri I, Ezehova Y, Giuliano T, Cacace V, Nusco E, De Risi M, De Leobinus E et al (2020) The amyloid inhibitor CLR01 relieves autophagy and ameliorates neuropathology in a severe lysosomal storage disease. Mol Ther 28: 1167 – 1176
Moro CA, Hanna-Rose W (2020) Animal model contributions to congenital metabolic disease. Adv Exp Med Biol 1236: 225 – 244
Mu TW, Ong DS, Wang YJ, Balch WE, Yates 3rd JR, Segatori L, Kelly JW (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769 – 781
Napolitano G, Di Malta C, Esposito A, de Araujo MEG, Pece S, Bertalot G, Matarese M, Benedetti V, Zampelli A, StaWyk T et al (2020) A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube’ syndrome. Nature 585: 597 – 602
Naureckiene S, Sileat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P (2000) Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 290: 2298 – 2301

Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Kooi T, Mora M, Riggs JE, Oh SJ, Koga Y et al (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 406: 906 – 910

Novikov AB, Beauzey AB, de Duve C (1956) Electron microscopy of lysosome rich fractions from rat liver. J. Biophys Biochem Cytol. 2: 179 – 184

Orri K, Lim A, Tomatsu S, Stapleton M, Suzuki Y, Simonaro CM, Schuchman EH, Fukuo T, Matsumoto T (2019) Safety study of sodium pentosan polysulfate for adult patients with mucopolysaccharidosis type II. Diagnostics 9, 226

Pan C, Nelson MS, Kodie L,Brazil JJ, Stephenson EJ, Zhao RC, Orii K, Lim A, Tomatsu S, Stapleton M, Suzuki Y, Simonaro CM, Schuchman EH, Fukuo T, Matsumoto T (2019) Safety study of sodium pentosan polysulfate for adult patients with mucopolysaccharidosis type II. Diagnostics 9, 226

Pardridge WM, Boado RJ, Giugliani R, Schmidt M (2018) Plasma pharmacokinetics of valanfusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in patients with mucopolysaccharidosis type I. BioDrugs 32: 169 – 176

Parenti G, Fecarotta S, la Marca G, Rossi B, Ascione S, Donati MA, Morandi LO, Ravaglia S, Picchietto A, Ombrone D et al (2014) A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 22: 2004 – 2012

Parenti G, Andria G, Ballabio A (2015a) Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med 66: 471 – 486

Parenti G, Andria G, Valenzano KJ (2015b) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23: 1138 – 1148

Parker H, Bigger BW (2019) The role of innate immunity in mucopolysaccharide diseases. J Neurochem 148: 639 – 651

Pastores GM, Torres PA, Zeng BJ (2013) Animal models for lysosomal storage disorders. Biochemistry. 78: 721 – 725

Pastores GM, Barnett NL (2003) Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin Invest Drugs 12: 273 – 281

Pavlova EV, Shatunov A, Wartsch L, Moskvina AI, Nikolaeva LE, Bright NA, Tylee KL, Church HJ, Ballabio A, Luzio JP et al (2019) The lysosomal disease caused by mutant VPS3A. Hum Mol Genet 28: 2514 – 2530

Peck SH, Tobias JW, Shore EM, Malhotra NR, Haskins ME, Casal ML, Smith LJ (2019) Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone 128: 115042

Pellegrini D, Del Grosso A, Angelina L, Giordano N, Dilillo M, Tonazzini I, Cafio M, Cecchini M, McDonnell LA (2019) Quantitative microproteomics based characterization of the central and peripheral nervous system of a mouse model of krabbe disease. Mol Cell Proteomics 18: 1227 – 1241

Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforet P, Mengel KE, Pestronk A, Pouget J et al (2019) Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy alglucosidase alpha (neoGAA) in treatment-naive and alglucosidase alpha-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neurourol Urodyn 29: 1267 – 1268

Pereira VG, Martins AM, Michielti C, D’Almeida V (2008) Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin Chim Acta 387: 75 – 79

Pergande MR, Nguyen TTA, Haney-Ball C, Davidson CD, Cologna SM (2019) Quantitative, label-free proteomics in the symptomatic niemann-pick, type C1 mouse model using standard flow liquid chromatography and thermal focusing electrospray ionization. Proteomics 19: e1800432

Percival BC, Gibson M, Wilson PB, Platt FM, Grootveld M (2020) Metabolomic studies of lipid storage disorders, with special reference to niemann-pick type C disease: a critical review with future perspectives. Int J Mol Sci 21: 2333

Perea RM, Zoncu R (2016) The lysosome as a regulatory hub. Annu Rev Cell Dev Biol 32: 223 – 253

Petcherski A, Chandrachud U, Butz ES, Klein MC, Zhao WN, Reis SA, Haggarty SJ, Ruonala MO, Cotman SL (2019) An autophagy modifier screen identifies small molecules capable of reducing autophagosome accumulation in a model of CLN3-mediated neurodegeneration. Cells 8: 1531

Pshehzetary AV (2015) Crosstalk between 2 organelles: lysosomal storage of heparan sulfate causes mitochondrial defects and neuronal death in mucopolysaccharidosis III type C. Rare Dis 3(1): e1049793

Pipalia NH, Huang A, Ralph H, Rujoj M, Maxfield FR (2008) Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells. J Lipid Res 47: 284 – 301

Platt FM (2018) Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov 17: 133 – 150

Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tiff CJ (2018) Lysosomal storage diseases. Nat Rev Dis Primers 4: 27

Plotkegh N, Duchen MR (2017) Mitochondrial dysfunction and neurodegeneration in lysosomal storage disorders. Trends Mol Med 23: 116 – 134

Polo G, Burlina AP, Ranieri E, Colucci F, Rubert L, Pascarella A, Duro G, Tumolo A, Padoan A, Plebani M et al (2019) Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study. Clin Chem Lab Med 57: 1863 – 1874

Porto C, Cardone M, Fontana F, Rossi B, Tuzzi MR, Tarallo A, Barone MV, Andria G, Parenti G (2009) The pharmacological chaperone N-butyldexoyojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 17: 964 – 971

Porto C, Ferrara MC, Meli M, Acampora E, Avolio V, Rosa M, Cubocciponzano B, Colombo G, Moracci M, Andria G et al (2012) Pharmacological enhancement of α-glucosidase by the allosteric chaperon N-acetylcysteine. Mol Ther. 20: 2201 – 2211

Poswar FQ, Vairo F, Burin M, Michelin-Tirelli K, Brusius-Facchin AC, Kubaski F, Souza CFM, Baldo G, Giugliani R (2019) Lysosomal diseases: Overview on current diagnosis and treatment. Genet Mol Biol 42(suppl 1): 165 – 177

Potter GB, Петриянка MA (2016) Neuroimmune mechanisms in Krabbe’s disease. J Neurosci Res 94: 1341 – 1348

Praggastis M, Tortelli B, Zhang J, Fujiwara H, Sidhu R, Chacko A, Chen Z, Chung C, Lieberman AP, Sikora J et al (2015) A murine Niemann-Pick C1 i1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. J Neurosci 35: 8091 – 8106

Probert F, Ruiz-Rodado V, Vruchte DT, Nicoli ER, Claridge TDW, Wassif CA, Farhat N, Porter FD, Platt FM, Grootveld M (2017) NMR analysis reveals significant differences in the plasma metabolic profiles of Niemann-Pick C1 patients, heterozygous carriers, and healthy controls. Sci Rep 7: 6320

Puerrattolo R, Ferguson SM, Brugara J, Ballabio A (2018) The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J 37: e98804

Pugach EK, Feltes M, Kaufman RJ, Ory DS, Bang AG (2018) High-content screen for modifiers of Niemann-Pick type C disease in patient cells. Hum Mol Genet 27: 2101 – 2112
Rabanal-Ruiz Y, Korolchuk VI (2018) mTORC1 and nutrient homeostasis: the central role of the lysosome. *Int J Mol Sci* 19: 818

Raben N, Puertollano R (2016) TFEB and TFE3: linking lysosomes to cellular adaptation to stress. *Annu Rev Cell Dev Biol* 32: 255–278

Ranieri E, Gerace RL, Ravenscroft EM, Hopwood JJ, Meikle PJ (1999) Pilot neonatal screening program for lysosomal storage disorders, using lamp-1. Southeast Asian. *J Trop Med Public Health* 30: 111 – 113

Ren H, Wang G (2020) Autophagy and lysosome storage disorders. *Adv Exp Med Biol* 1207: 87 – 102

Reunert J, Lutz-Havlav AS, Polo G, Kannenberg F, Fokker M, Griese M, Mengel E, Muntau AC, Schnabel P, Sommerburg O et al (2015) Niemann-Pick Type C-2 disease: identification by analysis of plasma cholestane-3β,5α,6β-triol and further insight into the clinical phenotype. *JIMD Rep* 23: 17 – 26

Rocznia-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, Walterm TC, Ferguson SM (2012) The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. *Sci Signal* 5: ra42

Saffari A, Kölker S, Hoffmann GF, Ebrahimi-Fakhari D (2017) Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases. *J Inherit Metab Dis* 40: 631 – 640

Saftig P, Klumperman J (2009) Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. *Nat Rev Mol Cell Biol* 10: 623 – 635

Salvato M, D’Avanzo F, Rigon L, Zanetti A, D’Angelo M, Valle G, Scarpa M, Tomanin R (2017) Brain RNA-Seq profiling of the mucopolysaccharidoses type II mouse model. *Int J Mol Sci* 18: 1072

Sambri I, D’Alessio R, Ezeka Y, Giuliano T, Sorrentino NC, Cacace V, De Risi M, Cataldi M, Annunziato L, De Leonibus E et al (2017) Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases. *EMBO Mol Med* 9: 112 – 132

Saunders MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. *Mol Ther* 13: 839 – 849

Santos R, Amaral O (2019) Advances in sphingolipidoses: CRISPR-Cas9 editing as an option for modelling and therapy. *Int J Mol Sci* 20: 5897.

Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Giancarlo Parenti et al (2017) Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, including clinical and biological considerations. *J Trop Med Public Health* Southeast Asian.

Schatz A, Ayati T, Specchio N, de Los RE, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D et al (2018) Study of intraventricular cerliponase alfa for CLN2 disease. *N Engl J Med* 378: 1898 – 1907

Scott CR, Elliott S, Hong X, Huang JY, Kumar AB, Yi F, Pendem N, Chennamanneni NK, Gelb MH (2020) Newborn screening for mucopolysaccharidoses: results of a pilot study with 100 000 dried blood spots. *J Pediatr* 216: 204 – 207

Scotto Rosato A, Montefusco S, Soldati C, Di Paola S, Capuozzo A, Monfregola J, Poloticka E, Amabile A, Cirmi M, Lombardo A et al (2019) TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway. *Nat Commun* 10: 630

Seemann S, Ernst M, Chimmaruta S, Struckmann S, Cozma C, Koczan D, Kneso AM, Haake LR, Citro V, Bräuer AU et al (2020) Proteostasis regulators modulate prosaposin activity and gene expression to attenuate multiple phenotypes in Fabry disease. *Biochem J* 477: 359 – 380

Sessa M, Lconti L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Callabria A et al (2016) Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. *Lancet* 388: 476 – 487

Settembre C, Fraldi A, Jainak M, Spampanato C, Venturi C, Medina D, de Pablo R, Tacchetti C, Rubinstein DC, Ballabio A (2008a) A block of autophagy in lysosomal storage disorders. *Hum Mol Genet* 17: 119 – 129

Settembre C, Arteaga-Solis E, Mckee MD, de Pablo R, Al Awqati Q, Ballabio A, Karsenty G (2008b) Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the extent of FGF signaling during endochondral ossification. *Genes Dev* 22: 2645 – 2650

Settembre C, Di Mastra C, Polito VA, García Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P et al (2011) TFEB links autophagy to lysosomal biogenesis. *Science* 332: 1429 – 1433

Settembre C, Zocca R, Medina DL, Vetrini F, Erdin S, Erdin SU, Huynh T, Ferron M, Karsenty G, Vellard MC et al (2012) A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J* 31: 1095 – 1108

Settembre C, Fraldi A, Medina DL, Ballabio A (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol* 14: 283 – 296

Settembre C, Cinque L, Bartolomeo R, Di Mastra C, De Leonibus C, Forrester A (2018) Defective collagen proteostasis and matrix formation in the pathogenesis of lysosomal storage disorders. *Matrix Biol* 71–72: 283 – 293

Shea L, Raben N (2009) Autophagy in skeletal muscle: implications for Pompe disease. *Int J Clin Pharmacol Ther* 47(Suppl 1): S42 – S47

Shachar T, Lo Bianco C, Cecchia R, Wiessner C, Raas-Rothschild A, Futterman AH (2011) Lysosomal storage disorders and Parkinson’s disease: Gaucher disease and beyond. *Mou Disord* 26: 1593 – 1604

Shin SD, Shin A, Mayagoitia K, Wilson CG, Bellinger DL, Soriano S (2017) Newborn screening for Niemann-Pick disease type C. *J Inherit Metab Dis* 40: 1170 – 1177

Shinde V, Sharmin S, Shinde S, Wagh S, Bhandare S, Desai A, Jagtap R, Derakhshan K, Deshmukh R, Upreti G et al (2017) Expression profile of inflammation-related genes in patients with Niemann-Pick disease type C. *PLoS One* 12: e0179447

Schröder BA, Wrocklage C, Hasilik A, Saftig P (2010) The proteome of lysosomes. *Proteomics* 10: 4053 – 4076

Shen H, Wang Y, Hao X, Zhang Z, Wang J, Ren H, Wang J, Zeng J, Shi Y (2012) Identification and validation of autophagy-related genes in human primary neurons. *PLoS One* 7: e46436

Sivaraman M, Mohan M, Manivasan S, Ramesh K, Viswanath N, Sivasankaran J, Divya S, Suresh N, Manohar S, Selvaraj S et al (2016) Identification of a novel splice acceptor variant in LAMP2 gene in a Pompe disease patient. *PLoS One* 11: e0153136
Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Tarallo A, Carissimo A, Gatto F, Nusco E, Toscano A, Musumeci O, Coletta M, Tardieu M, Zérah M, Gougeon ML, Ausseil J, de Bourbonville S, Husson B, Zafeiriou D, Parenti G, Bourget P, Poirier B et al (2017) Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol 16: 712–720

Tebani A, Abilly-Donval L, Schmitz-Afonso I, Piraud M, Ausseil J, Zermech F, Pilon C, Perea T, Marret S, Afonso C et al (2019) Analysis of mucopolysaccharidosis type VI through integrative functional metabolomics. Int J Mol Sci 20: 446

The UniProt Consortium (2019) UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 47: D506 – D515

Thelen M, Winter D, Braulke T, Gieselmann V (2017) Sialidosis type VI revealed by newborn screening. Am J Hum Genet 91: 12836 – 12837

Tobias P, Pathamasin KC, Cologna SM (2019) Mass spectrometry imaging reveals ganglioside and ceramide localization patterns during cerebellar degeneration in the Npc1−/− mouse model. Analyst Bioanalyt Chem 411: 5659 – 5668

Turner SM, Falk DJ, Byrne BJ, Fuller DD (2016) Transcriptome assessment of the Pompe (Gaa−/−) mouse spinal cord indicates widespread neuropathology. Physiol Genomics 48: 785 – 794

Utz JR, Crutcher T, Schneider J, Sorgen P, Whitley CB (2015) Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. Mol Genet Metab 118: 274 – 281

van der Wal E, Bergsma AJ, Pijnenburg JM, van der Ploeg AT, Pijnappel WWMP (2017) Antisense oligonucleotides promote exon inclusion and correct the common c.-32–137T>G GAA splicing variant in Pompe disease. Mol Ther Nucleic Acids 7: 90 – 100

van Gelder CM, Vollebregt AA, Plug I, van der Ploeg AT, Reuser AJ (2015) Treatment options for lysosomal storage disorders: developing insights. Expert Opin Pharmacother 16: 2281 – 2299

Van Hoof F (1974) Mucopolysaccharidoses and mucolipidoses. J Clin Pathol Suppl: 64 – 93

Vaqueur G, Rivière F, Mavris M, Bignami F, Llinares-Garcia J, Westermark B, Sepodes B (2013) Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat Rev Drug Discov 12: 287 – 305

Vellodi A (2009) Lysosomal storage disorders. Br J Haematol 145: 218 – 239

Vellutini KM, Nardocci N, Kaiyrzhanov R, Batten Disease). J Clin Med. 2020)

Villani CR, Di Domenico C, Musella A, Caccetti F, Di Napoli D, Di Natale P (2009) Mucopolysaccharidosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res 1279: 99 – 108

von Zastrow M, Sorkin A (2007) Intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 187: 67 – 85

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mice models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532

Sleat DE, Wiseman JA, El-Banna M, Zheng H, Zhao C, Soherwardy A, Moore DF, Lobel P (2019) Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics 18: 2244 – 2261

Sly WS, Fischer HD (1982) The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes. J Cell Biol 89: 1532 – 1533

Sleat DE, Donnelly RJ, Lackland H, Liu CC, Sohar I, Pullarkat RK, Lobel P (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277: 1802 – 1805

Sleat DE, Lackland H, Wang Y, Sohar I, Xiao G, Li H, Lobel P (2005) The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5: 1520 – 1532
Yuan X, Meng Y, Chen C, Liang S, Ma Y, Jiang W, Duan J, Wang C (ª2021) Proteomic approaches in the discovery of potential urinary biomarkers of mucopolysaccharidosis type II. Clin Chim Acta 499: 34 – 40

Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, Kan YW (2014) Seamless gene correction of beta-thalassemia mutations in patient specific iPSCs using CRISPR/Cas9 and piggybac. Genome Res 24: 1526 – 1533

Xu H, Martinoia E, Szabo I (2015) Organellar channels and transporters. Cell Calcium 58: 1 – 10

Xu H, Ren D (2015) Lysosomal physiology. Annu Rev Physiol 77: 57 – 80

Xu S, Lun Y, Frascella M, Frascella M, Garcia A, Soska R, Nair A, Ponery AS, Schilling A, Feng J et al (2019) Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight 4: e125358

Zalfa C, Verpelli C, D’Avanzo F, Tomanin R, Vidicodini C, Cajola L, Manara R, Sala C, Scarpa M, Vescovi AL et al (2016) Glial degeneration with oxidative damage drives neuronal demise in MPSII disease. Cell Death Dis 7: e2331

Zanella F, Lorenz JB, Link W (2010) High content screening: seeing is believing. Trends Biotechnol 28: 237 – 245

Zhang CK, Stein PB, Liu J, Wang Z, Yang R, Cho JH, Gregersen PK, Aerts JM, Zhao H, Pastores GM et al (2012) Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am J Hematol 87: 377 – 383

Zheng CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, Wu YQ, Li TY, Liang Y, Lu Z et al (2014) The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab 20: 526 – 540

Zervas M, Dobrenis K, Wallkey SJ (2003) Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 62: 49 – 64

Zhu X, Yin L, Theisen M, Siddiqui S, Levy B, Presnyak V, Frassetto A, Milton J, Salerno T, Benenato KE et al (2019) Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates. Am J Hum Genet 104: 625 – 637

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.